EyePoint Pharmaceuticals, Inc. (EYPT) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
EyePoint Pharmaceuticals, Inc. (EYPT) Bundle
Whether you're an investor or analyst, this (EYPT) DCF Calculator is your go-to resource for accurate valuation. Preloaded with real data from EyePoint Pharmaceuticals, Inc., you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.4 | 34.4 | 36.9 | 41.4 | 46.0 | 57.5 | 71.8 | 89.7 | 112.0 | 139.9 |
| Revenue Growth, % | 0 | 69.1 | 7.27 | 12.09 | 11.14 | 24.9 | 24.9 | 24.9 | 24.9 | 24.9 |
| EBITDA | -48.0 | -35.5 | -50.1 | -96.6 | -69.0 | -57.5 | -71.8 | -89.7 | -112.0 | -139.9 |
| EBITDA, % | -235.76 | -103.05 | -135.76 | -233.36 | -149.94 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.6 | 2.6 | 2.8 | 2.4 | .5 | 4.0 | 5.0 | 6.3 | 7.8 | 9.8 |
| Depreciation, % | 12.79 | 7.69 | 7.5 | 5.91 | 1.01 | 6.98 | 6.98 | 6.98 | 6.98 | 6.98 |
| EBIT | -50.6 | -38.1 | -52.9 | -99.1 | -69.5 | -57.5 | -71.8 | -89.7 | -112.0 | -139.9 |
| EBIT, % | -248.55 | -110.74 | -143.26 | -239.26 | -150.95 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 22.2 | 44.9 | 211.6 | 144.6 | 331.1 | 57.5 | 71.8 | 89.7 | 112.0 | 139.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 11.4 | 9.5 | 18.4 | 15.5 | .8 | 19.8 | 24.7 | 30.9 | 38.6 | 48.2 |
| Account Receivables, % | 55.82 | 27.45 | 49.69 | 37.44 | 1.75 | 34.43 | 34.43 | 34.43 | 34.43 | 34.43 |
| Inventories | 2.1 | 5.3 | 3.6 | 2.9 | 3.9 | 5.9 | 7.4 | 9.2 | 11.5 | 14.3 |
| Inventories, % | 10.5 | 15.5 | 9.79 | 6.97 | 8.49 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| Accounts Payable | 4.2 | 4.8 | 7.4 | 5.9 | 6.5 | 9.5 | 11.9 | 14.9 | 18.6 | 23.2 |
| Accounts Payable, % | 20.58 | 13.97 | 19.99 | 14.3 | 14.13 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 |
| Capital Expenditure | -.2 | -.4 | -.2 | -2.2 | -3.5 | -1.8 | -2.2 | -2.7 | -3.4 | -4.3 |
| Capital Expenditure, % | -1.05 | -1.05 | -0.42232 | -5.19 | -7.57 | -3.06 | -3.06 | -3.06 | -3.06 | -3.06 |
| Tax Rate, % | -0.11738 | -0.11738 | -0.11738 | -0.11738 | -0.11738 | -0.11738 | -0.11738 | -0.11738 | -0.11738 | -0.11738 |
| EBITAT | -56.1 | -44.2 | -57.9 | -120.6 | -69.5 | -57.5 | -71.8 | -89.7 | -112.0 | -139.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -63.0 | -42.6 | -59.9 | -118.2 | -58.3 | -73.2 | -73.0 | -91.2 | -113.9 | -142.2 |
| WACC, % | 11.85 | 11.85 | 11.85 | 11.85 | 11.85 | 11.85 | 11.85 | 11.85 | 11.85 | 11.85 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -342.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -145 | |||||||||
| Terminal Value | -1,473 | |||||||||
| Present Terminal Value | -841 | |||||||||
| Enterprise Value | -1,184 | |||||||||
| Net Debt | -276 | |||||||||
| Equity Value | -908 | |||||||||
| Diluted Shares Outstanding, MM | 39 | |||||||||
| Equity Value Per Share | -23.34 |
What You Will Get
- Real EYPT Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess EyePoint's future performance.
- User-Friendly Design: Crafted for professionals while remaining approachable for newcomers.
Key Features
- Customizable Forecast Inputs: Adjust essential parameters such as revenue growth, operating margin, and R&D expenditures.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and additional metrics in real-time.
- High-Precision Accuracy: Leverages EyePoint Pharmaceuticals' actual financial data for accurate valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the hassle of creating intricate valuation models from the ground up.
How It Works
- Download: Obtain the pre-formatted Excel file containing EyePoint Pharmaceuticals, Inc.'s (EYPT) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and assess results immediately.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Choose EyePoint Pharmaceuticals, Inc. (EYPT)?
- Innovative Solutions: Cutting-edge treatments designed to address unmet medical needs.
- Proven Track Record: A history of successful product development and commercialization.
- Dedicated Research: Commitment to advancing ocular therapeutics through rigorous research.
- Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
- Expert Team: Led by industry professionals with extensive experience in pharmaceuticals.
Who Should Use This Product?
- Investors: Evaluate EyePoint Pharmaceuticals' (EYPT) market potential and fair value prior to making investment choices.
- CFOs: Utilize a sophisticated DCF model for accurate financial reporting and analysis related to EyePoint Pharmaceuticals.
- Consultants: Efficiently customize the template for valuation reports tailored to EyePoint Pharmaceuticals' clients.
- Entrepreneurs: Discover financial modeling strategies employed by leading pharmaceutical companies.
- Educators: Incorporate it as a resource to teach valuation techniques in the pharmaceutical sector.
What the Template Contains
- Preloaded EYPT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.